Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Jorge Cortes

Title(s)Professor, Mechanical and Aerospace Engineering
SchoolVc-academic Affairs
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome. Blood Adv. 2025 Oct 28; 9(20):5293-5305. Cortes JE, Yang J, Roboz GJ, Dinner SN, Wang ES, Wei AH, Tian H, di Trapani F, Baer MR, Donnellan W, Watts JM. PMID: 40668616; PMCID: PMC12552956.
      View in: PubMed   Mentions:    Fields:    
    2. Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia. Leukemia. 2025 Nov; 39(11):2735-2744. Miranda-Galvis M, Tjioe KC, Sharara M, Maloney M, Keruakous AR, Jillella A, Kota V, Guha A, Cortes JE. PMID: 40935825.
      View in: PubMed   Mentions:    Fields:    
    3. Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey. Haematologica. 2026 Feb 01; 111(2):597-608. Lang F, Pemberton-Whiteley Z, Clements J, Ruiz C, Rea D, Machado L, Takahashi N, Moon SH, Grigg A, Borowczak C, Schuld P, Frank P, Constantinescu C, Boquimpani C, Cortes JE. PMID: 40637752.
      View in: PubMed   Mentions:    Fields:    
    4. Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY. Leuk Lymphoma. 2025 Sep; 66(9):1615-1624. Mauro MJ, Hehlmann R, Williams LA, Goldberg SL, Michallet M, Gambacorti-Passerini C, Tang D, DeGutis IS, McBride A, Parsons L, Montelongo M, Cortes JE. PMID: 40545759.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results. Leukemia. 2025 May; 39(5):1114-1123. Hochhaus A, Kim DW, Cortes JE, Sasaki K, Mauro MJ, Hughes TP, Breccia M, Talpaz M, Minami H, Goh YT, DeAngelo DJ, Lang F, Ottmann O, Heinrich MC, Gomez Garcia de Soria V, le Coutre P, Sanchez-Olle G, Cao M, Pognan N, Kapoor S, Hoch M, Rea D. PMID: 40204892; PMCID: PMC12055594.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    6. Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action. Expert Opin Pharmacother. 2025 Apr; 26(6):677-684. Jain AG, Cortes JE. PMID: 40087828.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    7. Bosutinib for the Treatment of CML-Using it Safely: a Podcast. Target Oncol. 2025 Mar; 20(2):183-189. Lipton JH, Cortes JE. PMID: 39821883; PMCID: PMC11933168.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. J Hematol Oncol. 2025 Jan 16; 18(1):7. Cortes JE, Roboz GJ, Baer MR, Jonas BA, Schiller GJ, Yee K, Ferrell PB, Yang J, Wang ES, Blum WG, Mims A, Tian H, Sheppard A, de Botton S, Montesinos P, Curti A, Watts JM, Olutasidenib Combination Therapy Study Group. PMID: 39819505; PMCID: PMC11736922.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    9. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. JAMA Oncol. 2025 Jan 01; 11(1):28-35. Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, Uspenskaya O, Samarina S, Mukherjee S, Cortes JE, Baer MR, Zherebtsova V, Shuvaev V, Turkina A, Davydkin I, Guo H, Chen Z, Fu T, Jiang L, Wang C, Wang H, Yang D, Zhai Y, Kantarjian H. PMID: 39570620; PMCID: PMC11583018.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    10. Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. J Hematol Oncol. 2024 12 18; 17(1):125. Hughes TP, Saglio G, Geissler J, Kim DW, Lomaia E, Mayer J, Turkina A, Kapoor S, Cardoso AP, Nieman B, Quenet S, Cortes JE. PMID: 39696526; PMCID: PMC11657281.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    11. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply. N Engl J Med. 2024 Dec 12; 391(23):2275-2276. Hochhaus A, Cortes JE, Hughes TP. PMID: 39665664.
      View in: PubMed   Mentions: 3     Fields:    
    12. Social determinants of health and upper gastrointestinal cancer outcomes in the United States: a systematic review. Front Public Health. 2024; 12:1477028. Santellano B, Agrawal R, Duchesne G, Sharara M, Agrawal G, Balas EA, Tsai MH, Nayak A, Cortes JE. PMID: 39628804; PMCID: PMC11613319.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. Future Oncol. 2024; 20(38):3065-3075. Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller P, Yang D, Laine D, Sabo J, Gu E, Cortes JE. PMID: 39387441.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    14. Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN. Haematologica. 2024 Oct 01; 109(10):3251-3260. Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Saglio G. PMID: 38695123; PMCID: PMC11443366.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    15. Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding. Clin Cancer Res. 2024 Sep 03; 30(17):3658-3666. Cortes JE, Abruzzese E, Cardonick EH, Hernández-Díaz S, Gutierrez J, Sardegna MS, Torres-Chavez E, Dinatale M, Lerro CC, Gehrke BJ, Shord SS, De Claro RA, Theoret MR, DeMaria PJ, Norsworthy KJ. PMID: 38967550; PMCID: PMC11371510.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. The intersection of melanoma survival and social determinants of health in the United States: A systematic review. JAAD Int. 2024 Dec; 17:126-138. Maloney ME, Bacak C, Tjioe K, Davis LS, Balas EA, Agrawal G, Cortes JE, Miranda-Galvis M. PMID: 39399338; PMCID: PMC11471241.
      View in: PubMed   Mentions: 2  
    17. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 08 01; 109(8):2660-2664. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. PMID: 38572554; PMCID: PMC11290543.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    18. Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia. Ann Hematol. 2024 Sep; 103(9):3429-3442. Lipton JH, Brümmendorf TH, Sweet K, Apperley JF, Cortes JE. PMID: 39023573; PMCID: PMC11358173.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States. Leuk Lymphoma. 2024 Nov; 65(11):1706-1715. Toreli ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, Miranda E, Fechio L, Silva Santos Duarte A, Basso A, Duarte G, Souza Medina S, Pericole F, Benites B, Jones K, Singh H, Farmaha J, Vashisht A, Kolhe R, Mondal AK, Saad STO, de Souza CA, Cortes JE, Pagnano K. PMID: 38967518.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    20. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024 09 12; 391(10):885-898. Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP, ASC4FIRST Investigators. PMID: 38820078.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    21. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia. Expert Rev Hematol. 2024 Jun; 17(6):211-221. Cortes JE. PMID: 38747392.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    22. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024 Jul; 38(7):1522-1533. Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. PMID: 38755421; PMCID: PMC11217003.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    23. Project Confirm: Accelerated Drug Approvals for CML-Response. Clin Cancer Res. 2024 01 05; 30(1):237-238. Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, Okusanya OO, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ. PMID: 38178776; PMCID: PMC10783534.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Haematologica. 2023 12 01; 108(12):3454-3459. Cortes JE, Lipton JH, Kota V, Castagnetti F, Assouline S, Brümmendorf TH, Leip E, Viqueira A, Gambacorti-Passerini C. PMID: 37439348; PMCID: PMC10690913.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    25. Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review. Blood Adv. 2023 11 14; 7(21):6466-6491. Miranda-Galvis M, Tjioe KC, Balas EA, Agrawal G, Cortes JE. PMID: 37639318; PMCID: PMC10632659.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    26. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 2023 10; 37(10):2017-2026. Sekeres MA, Montesinos P, Novak J, Wang J, Jeyakumar D, Tomlinson B, Mayer J, Jou E, Robak T, Taussig DC, Dombret H, Merchant A, Shaik N, O'Brien T, Roh W, Liu X, Ma W, DiRienzo CG, Chan G, Cortes JE. PMID: 37604981; PMCID: PMC10539167.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    27. Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer Med. 2023 09; 12(17):17981-17992. Garrett M, Knight B, Cortes JE, Deininger MW. PMID: 37553873; PMCID: PMC10524044.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    28. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):e369-e378. Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. PMID: 37690903; PMCID: PMC11427611.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers (Basel). 2023 Jun 16; 15(12). Sahajpal NS, Mondal AK, Singh H, Vashisht A, Ananth S, Saul D, Hastie AR, Hilton B, DuPont BR, Savage NM, Kota V, Chaubey A, Cortes JE, Kolhe R. PMID: 37370824; PMCID: PMC10296552.
      View in: PubMed   Mentions: 8  
    30. Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. Clin Cancer Res. 2023 06 13; 29(12):2179-2183. Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ. PMID: 36547666; PMCID: PMC10272032.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    31. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023 05; 37(5):1048-1059. Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Gómez-García de Soria V, le Coutre P, Mahon FX, Janssen JJWM, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F. PMID: 36949155; PMCID: PMC10169635.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    32. Teledermatology for skin cancer screening in rural Georgia utilizing teledermoscopy and distance learning: An ongoing report. JAAD Int. 2023 Jun; 11:140-142. Maloney ME, Miranda-Galvis M, Juarez BS, Mamouni K, Odhiambo L, Ibrahim S, Islam KMM, Markowitz RB, Desai K, Rabinovitz H, Buchanan K, Patten D, Davis LS, Cortes JE. PMID: 37128270; PMCID: PMC10148147.
      View in: PubMed   Mentions: 3  
    33. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Ther Adv Hematol. 2023; 14:20406207231154708. Swaminathan M, Cortes JE. PMID: 36845850; PMCID: PMC9943952.
      View in: PubMed   Mentions: 16  
    34. Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib. J Med Econ. 2023 Jan-Dec; 26(1):915-923. Cortes JE, Rea D, Mauro MJ, Tran D, Wang P, Jadhav K, Yocolly A, Sasaki K. PMID: 37431294.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170. Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, Bombaci F, Ramscar N, Ifrah S, Hughes TP. PMID: 36524980.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    36. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023 Jan; 10(1):e46-e58. Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. PMID: 36370742; PMCID: PMC12250719.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    37. Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial. J Hematol Oncol. 2022 10 26; 15(1):155. Cortes JE, Lin TL, Asubonteng K, Faderl S, Lancet JE, Prebet T. PMID: 36289532; PMCID: PMC9598030.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    38. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A. PMID: 35767897; PMCID: PMC9479031.
      View in: PubMed   Mentions: 1031     Fields:    Translation:Humans
    39. Characteristics of Cancer Survivors Living in Poverty in the United States: Results From the 2020 Behavioral Risk Factor Surveillance System Survey. JCO Oncol Pract. 2022 11; 18(11):e1831-e1838. Coughlin SS, Datta B, Williams LB, Bevel M, Cortes JE. PMID: 36067453.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    40. Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk? J Clin Oncol. 2022 11 10; 40(32):3719-3729. Casey M, Odhiambo L, Aggarwal N, Shoukier M, Garner J, Islam KM, Cortes JE. PMID: 35944216.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    41. Social needs and health-related quality of life among hematologic cancer survivors. Support Care Cancer. 2022 Nov; 30(11):8919-8925. Coughlin SS, Ayyala DN, Stewart JL, Cortes JE. PMID: 35895158.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    42. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022 07 11; 15(1):90. García-Gutiérrez V, Breccia M, Jabbour E, Mauro M, Cortes JE. PMID: 35818053; PMCID: PMC9272596.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansPHPublic Health
    43. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 07; 36(7):1825-1833. Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, Garcia-Gutierrez V, Chuah C, Kota V, Lipton JH, Rousselot P, Mauro MJ, Hochhaus A, Hurtado Monroy R, Leip E, Purcell S, Yver A, Viqueira A, Deininger MW, BFORE study investigators. PMID: 35643868; PMCID: PMC9252917.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    44. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022 11; 56:100968. Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, Garcia-Gutiérrez V, Deininger MW, Cortes JE. PMID: 35570071.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    45. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. Int J Hematol. 2022 Jun; 115(6):838-851. Takahashi N, Cortes JE, Sakaida E, Ishizawa K, Ono T, Doki N, Matsumura I, García-Gutiérrez V, Rosti G, Ono C, Ohkura M, Tanetsugu Y, Viqueira A, Brümmendorf TH. PMID: 35235189.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. Financial assistance programs for cancer patients. Curr Cancer Rep. 2021; 3(1):119-123. Coughlin SS, Dean LT, Cortes JE. PMID: 34568835; PMCID: PMC8462924.
      View in: PubMed   Mentions: 7  
    47. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias. Leuk Res. 2021 12; 111:106690. Kota V, Brümmendorf TH, Gambacorti-Passerini C, Lipton JH, Kim DW, An F, Leip E, Crescenzo RJ, Ferdinand R, Cortes JE. PMID: 34673442.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    48. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. PMID: 34340254.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    49. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. PMID: 33853292; PMCID: PMC8327731.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    50. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. J Hematol Oncol. 2021 07 13; 14(1):110. Cortes JE, Lin TL, Uy GL, Ryan RJ, Faderl S, Lancet JE. PMID: 34256819; PMCID: PMC8276472.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    51. Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021 Jul; 100(7):1917-1918. Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón JA, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G, Cortes JE. PMID: 33978823; PMCID: PMC8496603.
      View in: PubMed   Mentions:    Fields:    
    52. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491. Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE. PMID: 34171279.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    53. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 06 15; 14(1):94. Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. PMID: 34130720; PMCID: PMC8204504.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    54. Health care access and utilization among adult cancer survivors: Results from the National Institutes of Health "All of Us" Research Program. Cancer Med. 2021 06; 10(11):3646-3654. Coughlin SS, Chen J, Cortes JE. PMID: 33942535; PMCID: PMC8178490.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    55. Problems in living among breast cancer survivors. Curr Cancer Rep. 2021 Jun 15; 3(1):101-109. Coughlin SS, Ayyala DN, Cortes JE. PMID: 33937867; PMCID: PMC8086715.
      View in: PubMed   Mentions: 2  
    56. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021 Jul; 114(1):65-78. Chuah C, Koh LP, Numbenjapon T, Zang DY, Ong KH, Do YR, Ohkura M, Ono C, Viqueira A, Cortes JE, Brümmendorf TH. PMID: 33851349.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    57. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 08 01; 127(15):2641-2647. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. PMID: 33823073.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    58. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica. 2021 04 01; 106(4):1097-1105. Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W, Ning J, Short NJ, Ohanian M, Cortes JE, Jabbour EJ, Issa GC. PMID: 33297667; PMCID: PMC8586820.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    59. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021 03 23; 5(6):1719-1728. Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. PMID: 33724305; PMCID: PMC7993093.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    60. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021 Jun; 106(6):808-820. Cortes JE, Kantarjian HM, Mauro MJ, An F, Nick S, Leip E, Gambacorti-Passerini C, Brümmendorf TH. PMID: 33638218.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    61. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021 May; 100(5):1181-1194. Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón JA, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G, Cortes JE. PMID: 33740113; PMCID: PMC8043884.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    62. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. PMID: 32499238; PMCID: PMC7927994.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    63. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. PMID: 33618754; PMCID: PMC7901199.
      View in: PubMed   Mentions: 1     Fields:    
    64. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. PMID: 33449377; PMCID: PMC11949113.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    65. Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. Am J Hematol. 2021 04 01; 96(4):493-507. Cortes JE, Mehta P. PMID: 33368536; PMCID: PMC7986910.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    66. Knowledge of prostate cancer among African American men: A systematic review. Prostate. 2021 02; 81(3):202-213. Coughlin SS, Vernon M, Klaassen Z, Tingen MS, Cortes JE. PMID: 33368465.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    67. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma. 2021 04; 62(4):909-917. Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. PMID: 33283580.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    68. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. PMID: 33681815; PMCID: PMC7935111.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    69. Optimizing management of acute leukemia in community centers and when to refer. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):123-128. Jillella AP, Cortes JE, Kota VK. PMID: 33275676; PMCID: PMC7727530.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol. 2021 02 01; 96(2):241-250. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. PMID: 33180322; PMCID: PMC9022629.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    71. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer. 2021 04 15; 127(8):1246-1259. Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. PMID: 33270904.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    72. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020 10 15; 13(1):137. Cortes JE, de Lima M, Dombret H, Estey EH, Giralt SA, Montesinos P, Röllig C, Venditti A, Wang ES. PMID: 33059764; PMCID: PMC7559451.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    73. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. PMID: 33032648; PMCID: PMC7542942.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    74. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Transplant Cell Ther. 2021 02; 27(2):153-162. Ganguly S, Cortes JE, Krämer A, Levis MJ, Martinelli G, Perl AE, Russell NH, Arunachalam M, Santos CD, Gammon G, Lesegretain A, Mires DE, Pham H, Wang Y, Khaled SK. PMID: 33017662.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    75. Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leuk Lymphoma. 2020 12; 61(14):3287-3305. Cortes JE, Candoni A, Clark RE, Leber B, Montesinos P, Vyas P, Zeidan AM, Heuser M. PMID: 32967493.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. PMID: 32955970; PMCID: PMC11648456.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    77. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. 2020 Dec; 38(5):654-664. Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Kiladjian JJ, Rampal R, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, van Etten RA. PMID: 32592408; PMCID: PMC8895354.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    78. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. Cancer Chemother Pharmacol. 2020 10; 86(4):451-459. Lin S, Shaik N, Chan G, Cortes JE, Ruiz-Garcia A. PMID: 32885274; PMCID: PMC7515941.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    79. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020 11; 95(11):1296-1303. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. PMID: 32697348.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    80. Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. Blood Cancer Discov. 2020 Sep; 1(2):134-145. Jamieson C, Martinelli G, Papayannidis C, Cortes JE. PMID: 34661144; PMCID: PMC8447269.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    81. Financial distress among breast cancer survivors. Curr Cancer Rep. 2020; 2(1):48-53. Coughlin SS, Ayyala DN, Tingen MS, Cortes JE. PMID: 32984842; PMCID: PMC7518546.
      View in: PubMed   Mentions: 13  
    82. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020 Oct; 95(10):1127-1134. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. PMID: 32557828.
      View in: PubMed   Mentions: 5     Fields:    
    83. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. Cancer. 2020 10 01; 126(19):4315-4321. Solem CT, Bell TJ, Kwon Y, Cappelleri JC, Johnson C, Bhattacharyya H, Hoang CJ, Cortes JE. PMID: 32697335; PMCID: PMC7540307.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    84. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020 07 14; 13(1):92. Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P, Candoni A, Leber B, Sekeres MA, Pollyea DA, Ferdinand R, Ma WW, O'Brien T, O'Connell A, Chan G, Heuser M. PMID: 32664995; PMCID: PMC7362563.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    85. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. PMID: 32561839.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    86. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. PMID: 32546726; PMCID: PMC11450557.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    87. Pregnancy outcomes in patients treated with bosutinib. Int J Hematol Oncol. 2020 May 29; 9(2):IJH26. Cortes JE, Gambacorti-Passerini C, Deininger M, Abruzzese E, DeAnnuntis L, Brümmendorf TH. PMID: 33005329; PMCID: PMC7510513.
      View in: PubMed   Mentions: 12  
    88. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2020 05 12; 4(9):2032-2043. Lee JH, Faderl S, Pagel JM, Jung CW, Yoon SS, Pardanani AD, Becker PS, Lee H, Choi J, Lee K, Kim M, Cortes JE. PMID: 32396615; PMCID: PMC7218422.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    89. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 05 04; 10(5):47. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. PMID: 32366832; PMCID: PMC7198507.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    90. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1690-1699. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. PMID: 32330243; PMCID: PMC7189295.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    91. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. 2020; 143(6):567-573. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. PMID: 32289808; PMCID: PMC7839068.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    92. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020 08; 34(8):2064-2073. Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Gurnani R, Saglio G. PMID: 32265500; PMCID: PMC7387297.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    93. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. PMID: 32112433.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    94. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. PMID: 32099037; PMCID: PMC12136008.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    95. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. PMID: 31999839.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    96. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. PMID: 31999850; PMCID: PMC11385327.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    97. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. J Clin Oncol. 2020 04 01; 38(10):1006-1018. Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH, Winton EF, Parker DR, Lee H, Reister A, Savage S, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW. PMID: 31880950; PMCID: PMC7106977.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    98. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 12 12; 381(24):2315-2326. Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. PMID: 31826340; PMCID: PMC7724923.
      View in: PubMed   Mentions: 187     Fields:    Translation:HumansCTClinical Trials
    99. Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019 Dec; 17(12):686-696. Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ. PMID: 31851157.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    100. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020 03; 61(3):631-640. Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK. PMID: 31760835.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    101. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. PMID: 31665578.
      View in: PubMed   Mentions: 607     Fields:    Translation:HumansCTClinical Trials
    102. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 12; 94(12):1388-1395. Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. PMID: 31595534.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    103. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019 Nov; 15(31):3531-3545. Cortes JE, Dombret H, Merchant A, Tauchi T, DiRienzo CG, Sleight B, Zhang X, Leip EP, Shaik N, Bell T, Chan G, Sekeres MA. PMID: 31516032.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    104. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. PMID: 31400961; PMCID: PMC6778960.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    105. Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. Am J Hematol. 2019 10; 94(10):E256-E259. Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. PMID: 31273842.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    106. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov 01; 125(21):3755-3766. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. PMID: 31310323; PMCID: PMC11849279.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    107. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019 Aug; 6(8):e398-e408. Shih YT, Cortes JE, Kantarjian HM. PMID: 31208943; PMCID: PMC6658341.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    108. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 07; 20(7):984-997. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ. PMID: 31175001.
      View in: PubMed   Mentions: 243     Fields:    Translation:HumansCellsCTClinical Trials
    109. Tyrosine Kinase Inhibitor-associated Fibrothorax. Am J Respir Crit Care Med. 2019 06 01; 199(11):1432. Adrianza AM, Jimenez CA, Aldana GL, Pozo L, Cortes JE, Sagar AES. PMID: 30785770; PMCID: PMC6543723.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    110. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Curr Med Res Opin. 2019 09; 35(9):1615-1622. Cortes JE, Muresan B, Mamolo C, Cappelleri JC, Crescenzo RJ, Su Y, Gambacorti-Passerini C, Heeg B, Douglas Smith B. PMID: 30964361.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    111. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):509-515.e1. Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS. PMID: 31227358.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    112. Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev. 2019 Jun; 76:33-40. George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS. PMID: 31108240.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    113. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol. 2019 Jun; 145(6):1589-1599. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH, BFORE Study Investigators. PMID: 30989330; PMCID: PMC11810418.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    114. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861. Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. PMID: 30885996; PMCID: PMC6436011.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    115. Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases. JCO Precis Oncol. 2019; 3. Abou Dalle I, Bannon SA, Patel KP, Routbort MJ, Cortes JE, Ferrajoli A, Kontoyiannis DP, Wang SA, DiNardo CD. PMID: 32914014; PMCID: PMC7446369.
      View in: PubMed   Mentions: 3     Fields:    
    116. A second-generation TKI should always be used as initial therapy for CML. Blood Adv. 2018 12 26; 2(24):3653-3655. Cortes JE. PMID: 30587494; PMCID: PMC6306878.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    117. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. PMID: 30635233; PMCID: PMC11852403.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    118. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 02; 33(2):379-389. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M. PMID: 30555165; PMCID: PMC6365492.
      View in: PubMed   Mentions: 235     Fields:    Translation:HumansCTClinical Trials
    119. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. PMID: 30500073; PMCID: PMC6467779.
      View in: PubMed   Mentions: 174     Fields:    Translation:HumansCells
    120. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. PMID: 30409776; PMCID: PMC6397669.
      View in: PubMed   Mentions: 323     Fields:    Translation:HumansCTClinical Trials
    121. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019 01; 94(1):46-54. Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, Michallet M, Simonsson B, Williams LA, Gajavelli S, DeGutis I, Sen GP, Paquette RL. PMID: 30290003; PMCID: PMC6587733.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    122. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. PMID: 30318751; PMCID: PMC6246941.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    123. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. PMID: 30319961; PMCID: PMC6167965.
      View in: PubMed   Mentions: 24  
    124. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol. 2018 11; 93(11):1301-1310. Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA. PMID: 30074259; PMCID: PMC6221102.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    125. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. PMID: 30185431; PMCID: PMC6265645.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    126. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer J. 2018 09 03; 8(9):88. Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE. PMID: 30190469; PMCID: PMC6127283.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    127. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019 01; 104(1):93-101. Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE. PMID: 30093398; PMCID: PMC6312029.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    128. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. PMID: 30071517.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    129. Acute myeloid leukaemia. Lancet. 2018 08 18; 392(10147):593-606. Short NJ, Rytting ME, Cortes JE. PMID: 30078459; PMCID: PMC10230947.
      View in: PubMed   Mentions: 370     Fields:    Translation:Humans
    130. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. PMID: 30024784; PMCID: PMC6127025.
      View in: PubMed   Mentions: 406     Fields:    Translation:HumansCTClinical Trials
    131. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. PMID: 29991687; PMCID: PMC6039465.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    132. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018 08 09; 132(6):598-607. Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ. PMID: 29875101; PMCID: PMC6085992.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCellsCTClinical Trials
    133. Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. PMID: 29794146; PMCID: PMC6278965.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    134. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica. 2018 08; 103(8):1298-1307. Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ. PMID: 29773593; PMCID: PMC6068045.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    135. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. PMID: 29741984; PMCID: PMC6226369.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    136. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. PMID: 29702001; PMCID: PMC6008108.
      View in: PubMed   Mentions: 103     Fields:    Translation:Humans
    137. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. PMID: 29660836; PMCID: PMC6800041.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    138. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. PMID: 29645075.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    139. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. PMID: 29567798; PMCID: PMC6071555.
      View in: PubMed   Mentions: 275     Fields:    Translation:HumansCellsCTClinical Trials
    140. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. PMID: 29464484.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    141. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303. Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. PMID: 29463550.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCellsCTClinical Trials
    142. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res. 2018 04; 67:67-74. Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O. PMID: 29466766; PMCID: PMC6613209.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    143. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. PMID: 29266206; PMCID: PMC5851790.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    144. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017 Dec 12; 1(26):2541-2552. Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, Bai S, Lin P, Miranda RN, Jorgensen JL, McDonnell TJ, Wang W, Kantarjian HM, Hu S. PMID: 29296906; PMCID: PMC5728641.
      View in: PubMed   Mentions: 24     Fields:    
    145. Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates. Pharmacogenomics J. 2018 05 22; 18(3):436-443. Staquicini DI, D'Angelo S, Ferrara F, Karjalainen K, Sharma G, Smith TL, Tarleton CA, Jaalouk DE, Kuniyasu A, Baze WB, Chaffee BK, Hanley PW, Barnhart KF, Koivunen E, Marchiò S, Sidman RL, Cortes JE, Kantarjian HM, Arap W, Pasqualini R. PMID: 29205207; PMCID: PMC6824482.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    146. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):213-221. Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. PMID: 29139135; PMCID: PMC6586071.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    147. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. PMID: 29134664; PMCID: PMC12376909.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    148. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017; 6:30. Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. PMID: 29152412; PMCID: PMC5679503.
      View in: PubMed   Mentions: 18  
    149. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018 01 20; 36(3):231-237. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH. PMID: 29091516; PMCID: PMC5966023.
      View in: PubMed   Mentions: 200     Fields:    Translation:HumansCells
    150. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018 02 01; 124(3):587-595. Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Brümmendorf TH, Su Y, Reisman AL, Shapiro M, Lipton JH. PMID: 29072772; PMCID: PMC5813200.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    151. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017 Nov; 92(11):1214-1223. Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ. PMID: 28815757; PMCID: PMC5659133.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    152. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017 11 09; 130(19):2084-2091. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. PMID: 28835440; PMCID: PMC5680612.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    153. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. PMID: 28743165; PMCID: PMC5673547.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    154. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. PMID: 29296774; PMCID: PMC5727976.
      View in: PubMed   Mentions: 51     Fields:    
    155. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. PMID: 28718728; PMCID: PMC5773400.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    156. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. PMID: 28708931; PMCID: PMC5739034.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    157. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J. 2017 07 14; 7(7):e583. Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W, Tang G, Loghavi S, Luthra R, Yang W, Kantarjian HM, Hu S. PMID: 28708130; PMCID: PMC5549254.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    158. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk. 2017 10; 17(10):684-695.e6. Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Brümmendorf TH, Khoury HJ. PMID: 28807791.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    159. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. PMID: 28616864; PMCID: PMC6511975.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    160. Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]. Leuk Res. 2017 08; 59:65. Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. PMID: 28575698.
      View in: PubMed   Mentions: 1     Fields:    
    161. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 Jun 13; 1(14):863-866. Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. PMID: 29296729; PMCID: PMC5737601.
      View in: PubMed   Mentions: 1     Fields:    
    162. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. PMID: 28295472; PMCID: PMC5828013.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    163. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2017 07; 31(7):1654-1657. Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. PMID: 28400618; PMCID: PMC6192023.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    164. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. PMID: 28387922; PMCID: PMC5544569.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    165. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 01; 123(15):2875-2880. Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE. PMID: 28387926; PMCID: PMC5573914.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    166. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. PMID: 27655665; PMCID: PMC5400650.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    167. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017 03; 18(3):17. Bose P, Vachhani P, Cortes JE. PMID: 28286924.
      View in: PubMed   Mentions: 142     Fields:    Translation:Humans
    168. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. PMID: 28006851; PMCID: PMC5495018.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    169. Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer J. 2017 02 03; 7(2):e521. Chen Z, Medeiros LJ, Kantajian HM, Zheng L, Gong Z, Patel KP, Xiong H, Wang W, Cortes JE, Hu S. PMID: 28157214; PMCID: PMC5386338.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    170. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):348-355. DiNardo CD, Cortes JE. PMID: 27913501; PMCID: PMC6142505.
      View in: PubMed   Mentions: 124     Fields:    Translation:Humans
    171. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec; 3(12):e581-e591. Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, Huang X, Babu KG, Abdulkadyrov K, de Oliveira JSR, Shen ZX, Sacha T, Bendit I, Liang Z, Owugah T, Szczudlo T, Khanna S, Fellague-Chebra R, le Coutre PD. PMID: 27890073.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    172. Reply to K.R. Hoffman. J Clin Oncol. 2017 02 10; 35(5):567-568. Cortes JE, Hochhaus A. PMID: 29236618.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    173. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. PMID: 27763690; PMCID: PMC5293656.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    174. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. PMID: 27696391; PMCID: PMC5321542.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    175. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016 11; 50:123-131. Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. PMID: 27736729.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    176. Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leuk Lymphoma. 2017 03; 58(3):722-725. Maiti A, Cortes JE, Brown YD, Kantarjian HM. PMID: 27658536; PMCID: PMC5250544.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    177. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016 12; 91(12):1206-1214. Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, Matczak E, Leip E, Noonan K, Brümmendorf TH, Gambacorti-Passerini C. PMID: 27531525; PMCID: PMC5303616.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    178. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. PMID: 27602508; PMCID: PMC5321541.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    179. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. PMID: 27509035; PMCID: PMC5073019.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    180. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. PMID: 27508525; PMCID: PMC5321530.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    181. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S86-92. Hoehn D, Cortes JE, Medeiros LJ, Jabbour EJ, Hidalgo JE, Kanagal-Shamanna R, Bueso-Ramos CE. PMID: 27521332; PMCID: PMC5843379.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    182. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. PMID: 27479888; PMCID: PMC5321539.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCellsCTClinical Trials
    183. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016 09; 48:84-91. Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, Haluska FG. PMID: 27505637.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    184. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. PMID: 27178680; PMCID: PMC5558853.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    185. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol. 2016 08; 91(8):800-5. Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. PMID: 27169385; PMCID: PMC4946992.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    186. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74. Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G. PMID: 27192969; PMCID: PMC5094534.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    187. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66. Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. PMID: 27244347; PMCID: PMC5014667.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    188. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. PMID: 27235138; PMCID: PMC4965905.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCells
    189. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 07 10; 34(20):2333-40. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. PMID: 27217448; PMCID: PMC5118045.
      View in: PubMed   Mentions: 415     Fields:    Translation:HumansCTClinical Trials
    190. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016 08; 101(8):e324-7. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. PMID: 27175025; PMCID: PMC4967581.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    191. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer J. 2016 05 06; 6:e418. Chen Z, Wang W, Cortes JE, Liu E, Miranda RN, Zhao C, Yuan J, Lu X, Yang W, Ameri MD, Kantarjian HM, Medeiros LJ, Hu S. PMID: 27152845; PMCID: PMC4916296.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    192. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin. 2016 08; 32(8):1325-34. Whiteley J, Reisman A, Shapiro M, Cortes J, Cella D. PMID: 27045164.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    193. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016 06; 91(6):606-16. Cortes JE, Jean Khoury H, Kantarjian H, Brümmendorf TH, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C. PMID: 26971533; PMCID: PMC5548463.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    194. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21. Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW, EPIC investigators. PMID: 27083332.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCellsCTClinical Trials
    195. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma. 2016 12; 57(12):2863-2873. Chen LS, Yang JY, Liang H, Cortes JE, Gandhi V. PMID: 27054578; PMCID: PMC5650058.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    196. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 06 02; 127(22):2742-50. Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian HM, Medeiros LJ, Hu S. PMID: 27006386; PMCID: PMC4915795.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCellsCTClinical Trials
    197. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 01; 122(9):1398-407. Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP. PMID: 26998677; PMCID: PMC5071708.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    198. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. PMID: 26800008; PMCID: PMC5834229.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    199. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2016 07; 30(7):1606-9. Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian HM, Medeiros LJ, Hu S. PMID: 26837843; PMCID: PMC5115880.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    200. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia. 2016 07; 30(7):1593-6. le Coutre PD, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Gooden K, Wallis N, Cortes JE. PMID: 26686247; PMCID: PMC4935977.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    201. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res. 2016 Apr 01; 22(7):1687-98. Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE, Bankson JA, Cortes JE, Hart CP, Andreeff M, Konopleva M. PMID: 26603259; PMCID: PMC4818660.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    202. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12. Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S. PMID: 26603839; PMCID: PMC4760131.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    203. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016 Jan; 172(1):97-110. Brümmendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Conlan MG, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton JH. PMID: 26537529; PMCID: PMC4737299.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    204. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. PMID: 26492205; PMCID: PMC4826052.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    205. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. PMID: 26479889; PMCID: PMC4707980.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    206. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015 Dec; 90(12):1111-5. Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. PMID: 26348106; PMCID: PMC5115878.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    207. Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clin Proc. 2015 Oct; 90(10):1440-54. Thompson PA, Kantarjian HM, Cortes JE. PMID: 26434969; PMCID: PMC5656269.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    208. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016; 57(1):237-9. Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. PMID: 25904378; PMCID: PMC4712116.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    209. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. PMID: 26299958; PMCID: PMC4618182.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    210. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10; 13:294. Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O. PMID: 26357842; PMCID: PMC4566296.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    211. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. PMID: 26308885; PMCID: PMC4666803.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCellsCTClinical Trials
    212. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015 Oct 01; 126(14):1699-706. Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S. PMID: 26243778; PMCID: PMC4624442.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    213. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug; 1(5):643-51. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. PMID: 26181658.
      View in: PubMed   Mentions: 229     Fields:    Translation:HumansCTClinical Trials
    214. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904. Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE. PMID: 26217876; PMCID: PMC4519988.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    215. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015 Aug; 2(8):e339-46. Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C. PMID: 26688487.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    216. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov; 171(4):471-7. Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE. PMID: 26205361; PMCID: PMC4770883.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    217. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm. Int J Lab Hematol. 2015 Dec; 37(6):e150-2. Chen Z, Wang W, Verstovsek S, Cortes JE, Medeiros LJ, Hu S. PMID: 26086872.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    218. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6. Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. PMID: 26183878; PMCID: PMC4546869.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    219. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62. Sanford D, DiNardo CD, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. PMID: 26141213; PMCID: PMC4837956.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    220. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep; 90(9):755-68. Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE. PMID: 26040495; PMCID: PMC5132035.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    221. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3. Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. PMID: 25999449.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    222. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7. Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. PMID: 26012362; PMCID: PMC4547830.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    223. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93. Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. PMID: 26688093; PMCID: PMC4884053.
      View in: PubMed   Mentions: 147     Fields:    Translation:Humans
    224. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015 Jul; 100(7):898-904. Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE. PMID: 25887498; PMCID: PMC4486224.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    225. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2015 Nov; 29(11):2263-6. Wang W, Cortes JE, Lin P, Khoury JD, Ai D, Tang Z, Tang G, Jorgensen JL, Medeiros LJ, Hu S. PMID: 25931274.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    226. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015 Apr 08; 8:32. Wang W, Tang G, Cortes JE, Liu H, Ai D, Yin CC, Li S, Khoury JD, Bueso-Ramos C, Medeiros LJ, Hu S. PMID: 25888368; PMCID: PMC4396174.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    227. Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 01; 21(13):3041-51. Karjalainen K, Jaalouk DE, Bueso-Ramos C, Bover L, Sun Y, Kuniyasu A, Driessen WH, Cardó-Vila M, Rietz C, Zurita AJ, O'Brien S, Kantarjian HM, Cortes JE, Calin GA, Koivunen E, Arap W, Pasqualini R. PMID: 25779950; PMCID: PMC4490100.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    228. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):433-438.e2. Badar T, Cortes JE, Ravandi F, O'Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. PMID: 25795639; PMCID: PMC4509631.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    229. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015 Jul; 56(7):2092-7. Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. PMID: 25641433; PMCID: PMC4919663.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    230. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015 Apr; 122(2):391-8. Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K. PMID: 25666482; PMCID: PMC4369460.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    231. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15; 121(10):1637-44. Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE. PMID: 25586015; PMCID: PMC5650096.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    232. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. PMID: 26687423; PMCID: PMC4936479.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    233. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother. 2015 Jan; 16(1):95-106. DiNardo CD, Cortes JE. PMID: 25480777.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    234. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. J Clin Oncol. 2014 Sep 20; 32(27):3077. Kantarjian H, Cortes JE. PMID: 25002733.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    235. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015 Jan 15; 121(2):234-42. Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE. PMID: 25223583; PMCID: PMC5542857.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    236. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015 Jan; 168(1):69-81. Brümmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillié L, Pavlov D, Gogat K, Countouriotis AM, Gambacorti-Passerini C. PMID: 25196702; PMCID: PMC4274978.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    237. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. PMID: 24990142; PMCID: PMC4431614.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    238. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 Oct; 89(10):947-53. Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, Pavlov D, Gogat Marchant K, Duvillié L, Khattry N, Kantarjian HM, Brümmendorf TH. PMID: 24944159; PMCID: PMC4305212.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    239. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. PMID: 25042398; PMCID: PMC4239168.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    240. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. PMID: 24844364; PMCID: PMC4297591.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    241. Numb chin syndrome by precursor B acute lymphoblastic leukemia. Am J Hematol. 2014 Aug; 89(8):860-1. Romo CG, Jain P, Cortes JE. PMID: 24850438.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    242. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. PMID: 24737502; PMCID: PMC4124083.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    243. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22; 123(21):3239-46. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. PMID: 24687088; PMCID: PMC4624448.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCTClinical Trials
    244. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014 May 01; 20(9):2363-74. Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M. PMID: 24619500; PMCID: PMC4073635.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    245. Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2014 02 06; 370(6):577. Cortes JE, Talpaz M, Kantarjian H. PMID: 24499221.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    246. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40. Gandhi V, Plunkett W, Cortes JE. PMID: 24501394; PMCID: PMC4048124.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    247. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. PMID: 24487412; PMCID: PMC4091714.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    248. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. PMID: 24461514; PMCID: PMC4167660.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    249. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. PMID: 24492324; PMCID: PMC3981947.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    250. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014 Feb 27; 123(9):1309-18. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C. PMID: 24345751; PMCID: PMC4467890.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    251. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. PMID: 24332214; PMCID: PMC3959284.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    252. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Feb; 23(2):265-72. DiNardo CD, Cortes JE. PMID: 24313331.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    253. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study. Arch Pathol Lab Med. 2014 Sep; 138(9):1186-92. Akard LP, Cortes JE, Albitar M, Goldberg SL, Warsi G, Wetzler M, Ericson SG, Radich JP. PMID: 24308645.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    254. Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. Clin Investig (Lond). 2013 Dec 01; 3(12):1127-1138. Williams LA, Yucel E, Cortes JE, Cleeland CS. PMID: 24910769; PMCID: PMC4043382.
      View in: PubMed   Mentions: 2  
    255. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013 Dec; 13(12):1433-52. Jabbour EJ, Cortes JE, Kantarjian HM. PMID: 24236822; PMCID: PMC4181370.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    256. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 07; 369(19):1783-96. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators. PMID: 24180494; PMCID: PMC3886799.
      View in: PubMed   Mentions: 480     Fields:    Translation:HumansCTClinical Trials
    257. Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia. Cancer. 2014 Feb 15; 120(4):589-602. Karjalainen K, Pasqualini R, Cortes JE, Kornblau SM, Lichtiger B, O'Brien S, Kantarjian HM, Sidman RL, Arap W, Koivunen E. PMID: 24496871; PMCID: PMC4457455.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    258. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. PMID: 23913852; PMCID: PMC3849405.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    259. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10; 31(29):3681-7. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. PMID: 24002496; PMCID: PMC3804291.
      View in: PubMed   Mentions: 186     Fields:    Translation:HumansCellsCTClinical Trials
    260. CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. Am J Clin Pathol. 2013 Sep; 140(3):370-8. Chakhachiro ZI, Zuo Z, Aladily TN, Kantarjian HM, Cortes JE, Alayed K, Nguyen MH, Medeiros LJ, Bueso-Ramos C. PMID: 23955456.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    261. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):515-29. Jabbour EJ, Cortes JE, Kantarjian HM. PMID: 23890944; PMCID: PMC4160831.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    262. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res. 2013 Sep 15; 73(18):5775-86. Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW. PMID: 23887971; PMCID: PMC3894913.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    263. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. PMID: 23836561; PMCID: PMC3976223.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCells
    264. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. Br J Haematol. 2013 Oct; 163(1):130-2. Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH. PMID: 23829510; PMCID: PMC4128010.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    265. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. PMID: 23803709; PMCID: PMC4915804.
      View in: PubMed   Mentions: 798     Fields:    Translation:Humans
    266. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 01; 122(5):641-7. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE. PMID: 23777764; PMCID: PMC3731927.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    267. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):584-91. Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM. PMID: 23787123; PMCID: PMC3775895.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    268. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40. Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. PMID: 23763915; PMCID: PMC4114766.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    269. Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):579-83. Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H. PMID: 23763918; PMCID: PMC4341913.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    270. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. PMID: 23701251; PMCID: PMC3745781.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    271. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol. 2013 Aug; 162(4):548-52. Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. PMID: 23691988; PMCID: PMC3866040.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    272. Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications. Ann Oncol. 2013 Jul; 24(7):1873-1879. Raad II, Chaftari AM, Al Shuaibi MM, Jiang Y, Shomali W, Cortes JE, Lichtiger B, Hachem RY. PMID: 23519997; PMCID: PMC4990830.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    273. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. PMID: 23512829; PMCID: PMC4089101.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    274. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):307-14. Zheng W, Medeiros LJ, Hu Y, Powers L, Cortes JE, Ravandi-Kashani F, Kantarjian HH, Wang SA. PMID: 23313069; PMCID: PMC4188388.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    275. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):139-43. Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintás-Cardama A. PMID: 23276886; PMCID: PMC4114759.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    276. Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):153-8. Bhatt VR, Kantarjian H, Cortes JE, Ravandi F, Borthakur G. PMID: 23266036; PMCID: PMC3854973.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    277. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8. Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. PMID: 23260600; PMCID: PMC4098775.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    278. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. PMID: 23190221; PMCID: PMC3777383.
      View in: PubMed   Mentions: 327     Fields:    Translation:HumansCTClinical Trials
    279. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 01; 30(28):3486-92. Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C. PMID: 22949154; PMCID: PMC4979199.
      View in: PubMed   Mentions: 185     Fields:    Translation:HumansCTClinical Trials
    280. Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia. Hum Pathol. 2012 Dec; 43(12):2354-9. Hoehn D, Medeiros LJ, Kantarjian HM, Cortes JE, Wang X, Bueso-Ramos CE. PMID: 22939577; PMCID: PMC11776029.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    281. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. PMID: 22875630; PMCID: PMC3561428.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    282. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 2013 Jan; 27(1):113-7. Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE. PMID: 22772060.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    283. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. PMID: 22718840; PMCID: PMC4081158.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    284. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45. Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros LJ, Luthra R. PMID: 22642896; PMCID: PMC5707199.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    285. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 01; 118(23):5819-22. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. PMID: 22605576; PMCID: PMC4184417.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    286. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. PMID: 22585696; PMCID: PMC4879705.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    287. Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Clin Oncol. 2012 Jan 20; 30(3):223-4. Cortes JE. PMID: 22184376.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    288. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 02; 119(5):1123-9. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A. PMID: 22160483; PMCID: PMC4916556.
      View in: PubMed   Mentions: 230     Fields:    Translation:HumansCTClinical Trials
    289. Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. Haematologica. 2012 Feb; 97(2):235-40. Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur G. PMID: 22058194; PMCID: PMC3269483.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    290. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. PMID: 22015451; PMCID: PMC4110463.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    291. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011 Nov 10; 29(32):4260-5. Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintás-Cardama A, Garcia-Manero G, Rios MB, Cortes JE. PMID: 21990394; PMCID: PMC3221527.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    292. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011 Nov 20; 29(33):4417-23. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH. PMID: 21969499; PMCID: PMC3221524.
      View in: PubMed   Mentions: 161     Fields:    Translation:Humans
    293. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27; 118(17):4567-76. Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C. PMID: 21865346; PMCID: PMC4916618.
      View in: PubMed   Mentions: 188     Fields:    Translation:HumansCTClinical Trials
    294. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer. 2012 Feb 01; 118(3):848-55. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. PMID: 21751205; PMCID: PMC3919032.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    295. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011; 6(7):e22110. Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE, Issa JP. PMID: 21760961; PMCID: PMC3132778.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    296. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 2011 Jul 21; 118(3):693-702. Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. PMID: 21628411; PMCID: PMC3142906.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    297. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011 May 26; 117(21):5600-6. Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. PMID: 21467546; PMCID: PMC4186645.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    298. Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol. 2011 Jun 10; 29(17):e514-6. Vigil CE, Wang SA, Cortes JE, Bueso-Ramos C, Verstovsek S, Shinder R, Chen SS, Katz RL, Khanna A, Esmaeli B, Manning JT, You MJ, Miranda RN. PMID: 21464405; PMCID: PMC4874210.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    299. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res. 2011 Apr 01; 17(7):1674-83. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. PMID: 21307148; PMCID: PMC11749245.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    300. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 01; 29(7):789-96. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. PMID: 21220608; PMCID: PMC4979099.
      View in: PubMed   Mentions: 185     Fields:    Translation:HumansCTClinical Trials
    301. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer. 2010 Dec 15; 116(24):5659-66. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. PMID: 21218459; PMCID: PMC4185295.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    302. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011 May 01; 117(9):1800-11. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. PMID: 21509757; PMCID: PMC4180713.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    303. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011 May 15; 117(10):2145-55. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur G. PMID: 21523727; PMCID: PMC4184429.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    304. Targeting neuropilin-1 in human leukemia and lymphoma. Blood. 2011 Jan 20; 117(3):920-7. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. PMID: 21063027; PMCID: PMC3298438.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    305. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. PMID: 20952518; PMCID: PMC3012766.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCTClinical Trials
    306. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Sep 01; 116(17):4063-8. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN. PMID: 20564156; PMCID: PMC4181579.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    307. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma. 2010 Aug; 51(8):1478-84. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. PMID: 20658954; PMCID: PMC4188823.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    308. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010 May 01; 116(9):2174-9. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. PMID: 20162709; PMCID: PMC3753205.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    309. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. PMID: 20421540; PMCID: PMC4872315.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    310. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. PMID: 20212254; PMCID: PMC2930809.
      View in: PubMed   Mentions: 165     Fields:    Translation:HumansCTClinical Trials
    311. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010 Feb; 51(2):269-74. Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S. PMID: 20038218; PMCID: PMC4184061.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    312. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer. 2010 Jan 15; 116(2):369-76. Dimov ND, Medeiros LJ, Kantarjian HM, Cortes JE, Chang KS, Bueso-Ramos CE, Ravandi F. PMID: 19950129; PMCID: PMC4180261.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    313. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20; 28(3):398-404. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. PMID: 20008620; PMCID: PMC2815702.
      View in: PubMed   Mentions: 101     Fields:    Translation:Humans
    314. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010 Jan 20; 28(3):424-30. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. PMID: 20008622; PMCID: PMC4979244.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCTClinical Trials
    315. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010 Jan 20; 28(3):392-7. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. PMID: 20008621; PMCID: PMC2815701.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    316. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009 Oct 01; 27(28):4754-9. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J, Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group. PMID: 19720924; PMCID: PMC4979200.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    317. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer. 2009 Jul 15; 115(14):3217-21. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. PMID: 19441109; PMCID: PMC4184418.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    318. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer. 2009 Jul 01; 115(13):2912-21. Quintás-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM. PMID: 19402171; PMCID: PMC4176768.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    319. del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2009 Jul; 192(1):18-23. Yin CC, Abruzzo LV, Qiu X, Apostolidou E, Cortes JE, Medeiros LJ, Lu G. PMID: 19480932; PMCID: PMC4167428.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    320. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009 Aug 01; 27(22):3642-9. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D. PMID: 19506164; PMCID: PMC2799062.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    321. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. J Cell Mol Med. 2010 Jun; 14(6B):1777-92. Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R, Amin HM. PMID: 19508387; PMCID: PMC3444523.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    322. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009 Jul 20; 27(21):3472-9. Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM. PMID: 19487385; PMCID: PMC4979080.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    323. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. 2009 Sep; 23(9):1537-44. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. PMID: 19404318.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    324. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009 Apr; 16(2):122-31. Quintás-Cardama A, Kantarjian HM, Cortes JE. PMID: 19337198.
      View in: PubMed   Mentions: 94     Fields:    Translation:Humans
    325. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer. 2009 Apr 01; 115(7):1381-94. Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. PMID: 19195046.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    326. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009 Nov; 33(11):1481-4. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. PMID: 19193436; PMCID: PMC4184059.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    327. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 02; 84(2):161-9. Jabbour E, Cortes JE, Kantarjian HM. PMID: 19181650; PMCID: PMC2664587.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    328. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintás-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE. PMID: 19118067; PMCID: PMC4822510.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    329. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008 Sep 01; 113(5):985-94. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM. PMID: 18615627; PMCID: PMC4204653.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    330. Imatinib therapy for chronic myeloid leukemia: where do we go now? J Clin Oncol. 2008 Jul 10; 26(20):3308-9. Cortes JE. PMID: 18519950.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    331. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73. Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S. PMID: 18482053; PMCID: PMC4829954.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    332. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008 May 15; 112(10):2112-8. Jabbour E, Cortes JE, Kantarjian HM. PMID: 18348294; PMCID: PMC5141579.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    333. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008 May; 22(5):965-70. Quintás-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S. PMID: 18385750; PMCID: PMC4369783.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCellsCTClinical Trials
    334. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res. 2008 Jan 15; 14(2):509-14. Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM. PMID: 18223226.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    335. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008 Jan; 8(1):99-110. Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM. PMID: 18095887.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    336. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res. 2007 Jul; 31(7):891-7. Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitar M, Feldman EJ, Roboz GJ. PMID: 17560285.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    337. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007 Jun 01; 109(11):2171-81. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. PMID: 17431887.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    338. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007 Apr 01; 109(7):1355-9. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. PMID: 17326049.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    339. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol. 2007 Mar; 136(6):800-5. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. PMID: 17341265.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    340. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S4-14. Alvarez RH, Kantarjian H, Cortes JE. PMID: 17292736.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    341. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007 Jan 01; 109(1):315-22. Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S. PMID: 16912224.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    342. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006 Jul; 81(7):973-88. Quintás-Cardama A, Cortes JE. PMID: 16835977.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    343. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2006 Jun; 20(6):952-7. Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D, Feldman EJ. PMID: 16617323.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    344. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 01; 106(9):1974-84. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. PMID: 16583431.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    345. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006 Mar 15; 106(6):1306-15. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. PMID: 16463391.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    346. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia. 2005 Nov; 19(11):1905-11. Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM. PMID: 16151467.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    347. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr Mol Med. 2005 Nov; 5(7):615-23. Giles FJ, Cortes JE, Kantarjian HM. PMID: 16305488.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    348. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. PMID: 15863204.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    349. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004 Oct 01; 104(7):1979-88. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. PMID: 15198956.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    350. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):619-39, ix. Cortes JE, O'Brien SM, Giles F, Alvarez RH, Talpaz M, Kantarjian HM. PMID: 15271396.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    351. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol. 2004 Jun; 79(5):411-9. Borthakur G, Cortes JE. PMID: 15239390.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    352. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):753-74, xii. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. PMID: 15271404.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    353. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 01; 100(7):1449-58. Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. PMID: 15042679.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    354. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004 Apr; 125(2):187-95. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE. PMID: 15059141.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    355. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res. 2004 Apr; 28(4):353-7. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M. PMID: 15109534.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    356. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004 Apr 01; 22(7):1287-92. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. PMID: 15051776.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    357. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004 Jan 01; 100(1):116-21. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F, Cortes JE. PMID: 14692031.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    358. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. PMID: 12921945.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    359. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. PMID: 12921943.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    360. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer. 2003 Oct 01; 98(7):1430-7. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. PMID: 14508830.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    361. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 2003 Dec; 52(6):449-52. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. PMID: 13680159.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    362. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother. 2003 Sep; 37(9):1182-5. Giles FJ, Cortes JE, Halliburton TA, Mallard SJ, Estey EH, Waddelow TA, Lim JT. PMID: 12921496.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    363. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003 Dec 15; 102(13):4527-34. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM. PMID: 12947010.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    364. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003 Aug 15; 98(4):773-8. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. PMID: 12910522.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    365. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica. 2003 Jul; 88(7):733-6. Konopleva M, Cheng SC, Cortes JE, Hayes KJ, Pierce SA, Andreeff M, Giles FJ, O'Brien S, Kantarjian HM, Estey EH. PMID: 12857550.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    366. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2003 Sep; 52(3):223-8. Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O'Brien SM. PMID: 12783199.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    367. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003 Jun; 17(6):1100-3. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. PMID: 12764375.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCells
    368. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 2003 Sep; 52(3):229-34. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. PMID: 12783207.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    369. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003 May; 121(4):578-85. Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M. PMID: 12752098.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    370. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003 May 01; 21(9):1722-7. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. PMID: 12721247.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    371. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003 Sep 01; 102(5):1866-8. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. PMID: 12730116.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    372. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. PMID: 12660384.
      View in: PubMed   Mentions: 431     Fields:    Translation:HumansCells
    373. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. PMID: 12649163.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    374. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003 Mar 15; 21(6):1050-6. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. PMID: 12637470.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    375. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003 Mar; 9(3):976-80. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A, Kantarjian HM. PMID: 12631595.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    376. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003 Feb 15; 97(4):1033-41. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. PMID: 12569603.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    377. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May 15; 101(10):3794-800. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. PMID: 12560227.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    378. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol. 2002 Oct; 119(1):38-45. Giles FJ, Kantarjian HM, Bekele BN, Cortes JE, Faderl S, Thomas DA, Manshouri T, Rogers A, Keating MJ, Talpaz M, O'Brien S, Albitar M. PMID: 12358901.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    379. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002 Sep 01; 100(5):1590-5. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. PMID: 12176876.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    380. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003 Jan 01; 101(1):97-100. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M. PMID: 12393600.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    381. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002 Jul; 8(7):2177-87. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. PMID: 12114418.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    382. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002 Jul; 8(7):2167-76. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. PMID: 12114417.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    383. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002 Jul; 8(7):2134-41. Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. PMID: 12114413.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    384. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):26-30. Cortes JE, Kurzrock R, Kantarjian HM. PMID: 12214290.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    385. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):36-8. Kantarjian HM, Cortes JE, Rowe JM, Kurzrock R. PMID: 12214292.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    386. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002 Jun 15; 99(12):4343-9. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. PMID: 12036860.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    387. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002 Jun 01; 99(11):4222-4. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, Cortes JE, Kantarjian HM. PMID: 12010830.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    388. Troxacitabine activity in extramedullary myeloid leukemia. Hematology. 2002 Jun; 7(3):179-85. Alvarado Y, Kantarjian HM, Cortes JE, Apostolidou E, Bivins C, Giles FJ. PMID: 12243982.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    389. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr; 43(4):767-72. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. PMID: 12153163.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    390. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents. Invest New Drugs. 2002 Feb; 20(1):49-53. Hui YF, Giles FJ, Cortes JE. PMID: 12003194.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    391. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol. 2002 Feb 01; 20(3):656-64. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. PMID: 11821445.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    392. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002 Feb 01; 94(3):773-9. Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S, Kantarjian H. PMID: 11857312.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    393. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001 Dec 15; 98(13):3575-83. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. PMID: 11739159.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    394. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma. 2001 Jul; 42(3):329-37. Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette ES, Faderl S, Sarris A, Keating MJ, Giles FJ. PMID: 11699397.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    395. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001 Feb 01; 19(3):762-71. Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, Kantarjian HM. PMID: 11157029.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    396. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy. 2000 Oct; 20(10):1221-3. Hui YF, Cortes JE. PMID: 11034047.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    397. Autoantibodies to Abl and Bcr proteins. Leukemia. 2000 Sep; 14(9):1661-6. Talpaz M, Qiu X, Cheng K, Cortes JE, Kantarjian H, Kurzrock R. PMID: 10995014.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    398. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer. 1999 Apr 01; 85(7):1506-13. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ, Estey EH. PMID: 10193940.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    399. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 1999 Jan 01; 85(1):58-64. Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. PMID: 9921974.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    400. Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. Cancer. 1997 Aug 01; 80(3):396-400. Rodriguez-Monge EJ, Cortes JE, O'Brien S, Talpaz M, Kantarjian HM. PMID: 9241073.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    401. Chronic myelogenous leukemia: a review. Am J Med. 1996 May; 100(5):555-70. Cortes JE, Talpaz M, Kantarjian H. PMID: 8644769.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    402. Acute lymphocytic leukemia: a comprehensive review with emphasis on biology and therapy. Cancer Treat Res. 1996; 84:291-323. Cortes JE, Kantarjian H, Freireich EJ. PMID: 8724635.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    403. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer. 1995 Dec 15; 76(12):2393-417. Cortes JE, Kantarjian HM. PMID: 8625065.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
    404. Docetaxel. J Clin Oncol. 1995 Oct; 13(10):2643-55. Cortes JE, Pazdur R. PMID: 7595719.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansAnimalsCells
    405. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood. 1995 May 01; 85(9):2516-20. Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. PMID: 7537119.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    406. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer. 1995 Jan 15; 75(2):464-70. Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM. PMID: 7812917.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    407. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia. 1995 Jan; 9(1):115-7. Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estey E. PMID: 7845005.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    408. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer. 1994 Jun 15; 73(12):2946-52. Cortes JE, Kantarjian H, O'Brien S, Robertson LE, Koller C, Hirsh-Ginsberg C, Stass S, Keating M, Estey E. PMID: 8199992.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    409. Chronic myelogenous leukemia. Curr Opin Oncol. 1994 Jan; 6(1):23-31. Cortes JE, O'Brien S. PMID: 7515693.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Jorge's Networks
    Concepts (764)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-18-gb39b692b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California